{
  "ticker": "RVMD",
  "company_name": "Revolution Medicines, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT06162221",
      "title": "Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC",
      "start_date": "2024-01-18",
      "completion_date": "2028-12",
      "enrollment": 0,
      "sponsor": "Revolution Medicines, Inc."
    },
    {
      "nct_id": "NCT06881784",
      "title": "Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), NSCLC (Advanced Non-small Cell Lung Cancer)",
      "start_date": "2025-05-06",
      "completion_date": "2030-12-01",
      "enrollment": 0,
      "sponsor": "Revolution Medicines, Inc."
    },
    {
      "nct_id": "NCT05557292",
      "title": "RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Glioblastoma, Recurrent Glioblastoma",
      "start_date": "2023-04-03",
      "completion_date": "2030-04-30",
      "enrollment": 0,
      "sponsor": "Nicholas Butowski"
    },
    {
      "nct_id": "NCT06922591",
      "title": "Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer Metastatic, Thoracic Cancer",
      "start_date": "2025-05-31",
      "completion_date": "2027-12",
      "enrollment": 0,
      "sponsor": "Tango Therapeutics, Inc."
    },
    {
      "nct_id": "NCT05462717",
      "title": "Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "condition": "Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor",
      "start_date": "2022-09-19",
      "completion_date": "2025-12",
      "enrollment": 0,
      "sponsor": "Revolution Medicines, Inc."
    },
    {
      "nct_id": "NCT03989115",
      "title": "Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Solid Tumor",
      "start_date": "2019-07-02",
      "completion_date": "2022-02-08",
      "enrollment": 0,
      "sponsor": "Revolution Medicines, Inc."
    },
    {
      "nct_id": "NCT06040541",
      "title": "Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors",
      "start_date": "2023-09-07",
      "completion_date": "2027-04-30",
      "enrollment": 0,
      "sponsor": "Revolution Medicines, Inc."
    },
    {
      "nct_id": "NCT05379985",
      "title": "Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors",
      "start_date": "2022-05-31",
      "completion_date": "2027-07-26",
      "enrollment": 0,
      "sponsor": "Revolution Medicines, Inc."
    },
    {
      "nct_id": "NCT06445062",
      "title": "Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma",
      "start_date": "2024-05-24",
      "completion_date": "2027-07-15",
      "enrollment": 0,
      "sponsor": "Revolution Medicines, Inc."
    },
    {
      "nct_id": "NCT06625320",
      "title": "Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma",
      "start_date": "2024-10-16",
      "completion_date": "2027-12",
      "enrollment": 0,
      "sponsor": "Revolution Medicines, Inc."
    }
  ],
  "summary": {
    "total_trials": 16,
    "by_phase": {
      "PHASE1, PHASE2": 6,
      "PHASE3": 3,
      "PHASE1": 6,
      "PHASE2": 1
    },
    "by_status": {
      "RECRUITING": 9,
      "ACTIVE_NOT_RECRUITING": 2,
      "COMPLETED": 3,
      "TERMINATED": 1,
      "UNKNOWN": 1
    },
    "active_trials": 11,
    "completed_trials": 3,
    "conditions": [
      "Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma",
      "Glioblastoma, Recurrent Glioblastoma",
      "Metastatic Neoplasm",
      "NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), NSCLC (Advanced Non-small Cell Lung Cancer)",
      "Non-Small Cell Lung Cancer",
      "Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor",
      "Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma",
      "Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC",
      "Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors",
      "PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer Metastatic, Thoracic Cancer",
      "Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma",
      "Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma",
      "Solid Tumor",
      "Solid Tumors"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:44:46.983858",
    "search_query": "Revolution Medicines, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Revolution+Medicines,+Inc."
  }
}